These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38856035)

  • 21. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.
    Xuan L; Jiang X; Sun J; Zhang Y; Huang F; Fan Z; Guo X; Dai M; Liu C; Yu G; Zhang X; Wu M; Huang X; Liu Q
    Transplantation; 2013 Sep; 96(6):560-6. PubMed ID: 23842192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-uniform
    Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
    Front Immunol; 2019; 10():2489. PubMed ID: 31736946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD.
    Mensen A; Na IK; Häfer R; Meerbach A; Schlecht M; Pietschmann ML; Gruhn B
    J Cancer Res Clin Oncol; 2014 Nov; 140(11):1971-80. PubMed ID: 24962343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
    Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
    Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Posttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation.
    Nagle SJ; Reshef R; Tsai DE
    Clin Chest Med; 2017 Dec; 38(4):771-783. PubMed ID: 29128025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
    Kuriyama T; Kawano N; Yamashita K; Ueda A
    J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea.
    Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim HJ; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
    J Korean Med Sci; 2006 Apr; 21(2):259-64. PubMed ID: 16614511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.
    Fujimoto A; Hiramoto N; Yamasaki S; Inamoto Y; Ogata M; Sugio Y; Fukuda T; Uchida N; Ikegame K; Matsuoka KI; Shiratori S; Kondo T; Miyamoto T; Eto T; Ichinohe T; Kanda Y; Atsuta Y; Suzuki R;
    Hematol Oncol; 2020 Apr; 38(2):146-152. PubMed ID: 31953867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
    Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
    Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.
    Gärtner BC; Schäfer H; Marggraff K; Eisele G; Schäfer M; Dilloo D; Roemer K; Laws HJ; Sester M; Sester U; Einsele H; Mueller-Lantzsch N
    J Clin Microbiol; 2002 Feb; 40(2):351-8. PubMed ID: 11825941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Xu LP; Liu DH; Liu KY; Chen H; Han W; Wang Y; Wang J; Shi HX; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):955-8. PubMed ID: 21211211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
    Xu LP; Huang XJ; Liu DH; Chen YH; Shi HX; Chen DB
    Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):996-9. PubMed ID: 18478915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
    J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
    Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
    Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Bao X; Zhu Q; Qiu H; Chen F; Xue S; Ma X; Sun A; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):138-43. PubMed ID: 27014984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Dynamic monitoring of plasma Epstein-Barr Virus DNA load can predict the occurrence of lymphoproliferative disorders after haploidentical hematopoietic stem cell transplantation].
    Chen J; Sun YQ; Xu LP; Zhang XH; Liu KY; Mo XD; Cheng YF; Huang XJ; Wang Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):284-288. PubMed ID: 37356996
    [No Abstract]   [Full Text] [Related]  

  • 40. [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Han TT; Xu LP; Liu DH; Liu KY; Zhang XH; Chen H; Chen YH; Han W; Wang FR; Wang Y; Wang JZ; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):651-4. PubMed ID: 23978013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.